CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression

Chris Boulton, a former executive of Amgen Inc. (NASDAQ:AMGN), Sanofi (Euronext:SAN; NASDAQ:SNY) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN), will become CEO of  Prolynx Inc., an Emeryville, Calif.-based developer of ultra-long-acting peptide therapies for metabolic conditions, including obesity. Co-founder Daniel Santi, who has been serving as president, will become chief technical and scientific officer. Boulton was VP and global marketing therapy area head for obesity at Amgen. This week, the biotech raised a $70 million series A round co-led by 5AM Ventures and OrbiMed Advisors.

Centessa Pharmaceuticals plc (NASDAQ:CNTA) said Mario Alberto Accardi, president and founder of the biotech’s orexin program, will become CEO and a member of the board, effective Jan. 1. OX2R is emerging as a competitive target for narcolepsy. Accardi will succeed Saurabh Saha, who will step down from his post and the board. ...